Literature DB >> 11742534

Structural requirements of the interleukin-6 signal transducer gp130 for its interaction with Janus kinase 1: the receptor is crucial for kinase activation.

Claude Haan1, Peter C Heinrich, Iris Behrmann.   

Abstract

We analysed the interaction of gp130, the common signal-transducing receptor chain of interleukin (IL)-6 type cytokines, with Jak1, the Janus family kinase which is crucial for signal transduction of this group of cytokines. With a truncated chimaeric IL-5Rbeta-gp130 receptor expressed in COS-7 cells, we show that the membrane-proximal 69 amino acids are sufficient to mediate Jak1 binding and activation. Deletion of box2 drastically reduced binding of endogenous, but not of overexpressed, Jak1. Several point mutations in the membrane-proximal region of gp130 (W652A, P671/P672A, F676A, Y683F, where W, A, P, F and Y are tryptophan, alanine, proline, phenylalanine and tyrosine) did not affect Jak1 association. However, stimulation of chimaeric receptors with the mutations P671/P672A and F676A in the interbox1/box2 region resulted in a reduced activation of STAT (signal transducer and activator of transcription) transcription factors. Most importantly, signalling by the receptor with the box1 mutation W652A was totally abrogated. Although this mutation did not affect Jak1 association, stimulation-dependent phosphorylation of Jak1 was prevented. The W652 mutation acts dominantly, since no signalling occured even when only a single cytoplasmic chain of a gp130 dimer contained the mutation. Our data demonstrate that the mere proximity of Jaks in an activated receptor complex is not sufficient to mediate their activation. Rather, it seems that parts of the receptor, including the box1 region, are involved in positioning Jaks correctly so that ligand-induced receptor dimerization and reorientation can lead to their mutual activation and subsequently to downstream signalling events.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11742534      PMCID: PMC1222284          DOI: 10.1042/0264-6021:3610105

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  37 in total

1.  A single amino acid substitution (Trp(666)-->Ala) in the interbox1/2 region of the interleukin-6 signal transducer gp130 abrogates binding of JAK1, and dominantly impairs signal transduction.

Authors:  C Haan; H M Hermanns; P C Heinrich; I Behrmann
Journal:  Biochem J       Date:  2000-07-01       Impact factor: 3.857

2.  Studies on the interleukin-6-type cytokine signal transducer gp130 reveal a novel mechanism of receptor activation by monoclonal antibodies.

Authors:  G Müller-Newen; A Küster; J Wijdenes; F Schaper; P C Heinrich
Journal:  J Biol Chem       Date:  2000-02-18       Impact factor: 5.157

3.  The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif.

Authors:  S N Constantinescu; L J Huang; H Nam; H F Lodish
Journal:  Mol Cell       Date:  2001-02       Impact factor: 17.970

4.  The cytoplasmic tyrosine motifs in full-length glycoprotein 130 have different roles in IL-6 signal transduction.

Authors:  J Schmitz; H Dahmen; C Grimm; C Gendo; G Müller-Newen; P C Heinrich; F Schaper
Journal:  J Immunol       Date:  2000-01-15       Impact factor: 5.422

5.  Novel neurotrophin-1/B cell-stimulating factor-3: a cytokine of the IL-6 family.

Authors:  G Senaldi; B C Varnum; U Sarmiento; C Starnes; J Lile; S Scully; J Guo; G Elliott; J McNinch; C L Shaklee; D Freeman; F Manu; W S Simonet; T Boone; M S Chang
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

6.  Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1.

Authors:  M Kortylewski; P C Heinrich; A Mackiewicz; U Schniertshauer; U Klingmüller; K Nakajima; T Hirano; F Horn; I Behrmann
Journal:  Oncogene       Date:  1999-06-24       Impact factor: 9.867

7.  A pivotal role for the transmembrane domain in transforming growth factor-beta receptor activation.

Authors:  H J Zhu; A M Sizeland
Journal:  J Biol Chem       Date:  1999-04-23       Impact factor: 5.157

8.  Contributions of leukemia inhibitory factor receptor and oncostatin M receptor to signal transduction in heterodimeric complexes with glycoprotein 130.

Authors:  H M Hermanns; S Radtke; C Haan; H Schmitz-Van de Leur; J Tavernier; P C Heinrich; I Behrmann
Journal:  J Immunol       Date:  1999-12-15       Impact factor: 5.422

9.  Oligomerization and scaffolding functions of the erythropoietin receptor cytoplasmic tail.

Authors:  S S Watowich; K D Liu; X Xie; S Y Lai; A Mikami; G D Longmore; M A Goldsmith
Journal:  J Biol Chem       Date:  1999-02-26       Impact factor: 5.157

10.  Erythropoietin receptor activation by a ligand-induced conformation change.

Authors:  I Remy; I A Wilson; S W Michnick
Journal:  Science       Date:  1999-02-12       Impact factor: 47.728

View more
  17 in total

1.  Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies.

Authors:  Shashidhar S Jatiani; Stacey J Baker; Lewis R Silverman; E Premkumar Reddy
Journal:  Genes Cancer       Date:  2010-10

Review 2.  The use of structural biology in Janus kinase targeted drug discovery.

Authors:  Nilda L Alicea-Velázquez; Titus J Boggon
Journal:  Curr Drug Targets       Date:  2011-04       Impact factor: 3.465

3.  Identification of a novel function of the clathrin-coated structure at the plasma membrane in facilitating GM-CSF receptor-mediated activation of JAK2.

Authors:  Ping-Hung Chen; Fan-Ching Chien; Sue-Ping Lee; Woan-Eng Chan; I-Hsuan Lin; Chun-Shan Liu; Fang-Jen Lee; Jiann-Shiun Lai; Peilin Chen; Hsin-Fang Yang-Yen; Jeffrey Jong-Young Yen
Journal:  Cell Cycle       Date:  2012-08-30       Impact factor: 4.534

4.  Three lysine residues in the common β chain of the interleukin-5 receptor are required for Janus kinase (JAK)-dependent receptor ubiquitination, endocytosis, and signaling.

Authors:  Jonathan T Lei; Tuhina Mazumdar; Margarita Martinez-Moczygemba
Journal:  J Biol Chem       Date:  2011-09-30       Impact factor: 5.157

5.  Crystal Structure of a Complex of the Intracellular Domain of Interferon λ Receptor 1 (IFNLR1) and the FERM/SH2 Domains of Human JAK1.

Authors:  Di Zhang; Alexander Wlodawer; Jacek Lubkowski
Journal:  J Mol Biol       Date:  2016-10-07       Impact factor: 5.469

6.  Structural snapshots of full-length Jak1, a transmembrane gp130/IL-6/IL-6Rα cytokine receptor complex, and the receptor-Jak1 holocomplex.

Authors:  Patrick J Lupardus; Georgios Skiniotis; Amanda J Rice; Christoph Thomas; Suzanne Fischer; Thomas Walz; K Christopher Garcia
Journal:  Structure       Date:  2011-01-12       Impact factor: 5.006

7.  The Structural Basis for Class II Cytokine Receptor Recognition by JAK1.

Authors:  Ryan Ferrao; Heidi J A Wallweber; Hoangdung Ho; Christine Tam; Yvonne Franke; John Quinn; Patrick J Lupardus
Journal:  Structure       Date:  2016-04-28       Impact factor: 5.006

Review 8.  Principles of interleukin (IL)-6-type cytokine signalling and its regulation.

Authors:  Peter C Heinrich; Iris Behrmann; Serge Haan; Heike M Hermanns; Gerhard Müller-Newen; Fred Schaper
Journal:  Biochem J       Date:  2003-08-15       Impact factor: 3.857

9.  Evolution of JAK-STAT pathway components: mechanisms and role in immune system development.

Authors:  Clifford Liongue; Lynda A O'Sullivan; Monique C Trengove; Alister C Ward
Journal:  PLoS One       Date:  2012-03-07       Impact factor: 3.240

Review 10.  Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases.

Authors:  Claude Haan; Iris Behrmann; Serge Haan
Journal:  J Cell Mol Med       Date:  2010-01-28       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.